Compare AU
Compare CURE vs. CNEW
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck China New Economy ETF (CNEW). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 51 |
Median incremental investment | $624.65 | $750.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $1,918.68 |
Average age group | > 35 | > 35 |
Key Summary
CURE | CNEW | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | CNEW.AX was created on 2018-11-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. CNEW.AX gives investors a portfolio of the most fundamentally sound companies in China having the best growth prospects in sectors making up the New Economy, namely technology, health care, consumer staples and consumer discretionary. CNEW.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Shenzhen Sinexcel Electric Co Ltd Class A (1.20 %) Delton Technology (Guangzhou) Inc Ordinary Shares - Class A (1.17 %) Gambol Pet Group Co Ltd Class A (1.13 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (36.77 %) Consumer Staples (29.59 %) Information Technology (29.15 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | China (100.00 %) |
Management fee | 0.45 % | 0.95 % |
Key Summary
CURE | CNEW | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | CSI MarketGrader China New Economy Index - CNY |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.95 % |
Price | $46.83 | $7.28 |
Size | $33.491 million | $114.265 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 1.53 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 09/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 51 |
Median incremental investment | $624.65 | $750.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $1,918.68 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | CNEW | |
|---|---|---|
Pros |
| |
Cons |
|
CURE | CNEW |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |